Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals [Yahoo! Finance]
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? [Yahoo! Finance]
Immunome (NASDAQ:IMNM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)